GlassScriptPhysician profile
Mary L Mattei
NPI 1619251568
$9,948.74
in general payments reported to CMS, 2019-2025
55 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what 98% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,004 · 2022: $1,578 · 2023: $2,211 · 2024: $2,349 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,366.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $1,800.00 | 2021 | |
| Eisai INC. | $1,002.68 | 2021-2025 | |
| Janssen Biotech, INC. | $766.11 | 2021-2025 | Erleada, Balversa, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $743.54 | 2022-2025 | Libtayo, Lynozyfic |
| Novartis Pharmaceuticals Corporation | $593.28 | 2022-2025 | |
| Daiichi Sankyo INC. | $546.57 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $491.43 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $462.46 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $324.20 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $291.05 | 2022-2025 | Jemperli, Zejula |
| Genzyme Corporation | $238.77 | 2022-2025 | |
| Pfizer INC. | $205.08 | 2023-2025 | |
| Tersera Therapeutics LLC | $204.73 | 2023-2025 | Zoladex, Quzyttir, Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $186.94 | 2022-2024 | Iclusig, Alunbrig, Ninlaro |
| Genentech USA, INC. | $174.95 | 2022-2025 | Polivy, Lunsumio, Itovebi |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $138.04 | 2022-2023 | Adcetris, Tivdak, Padcev |
| Pharmaessentia USA Corporation | $128.26 | 2023-2025 | Besremi |
| Exelixis INC. | $123.37 | 2021-2024 | Cabometyx |
| Amgen INC. | $108.45 | 2021-2023 | Kyprolis |
| Pharmacosmos Therapeutics INC. | $107.93 | 2022-2025 | Monoferric, Cosela |
| Beigene USA, INC. | $82.50 | 2022-2024 | Brukinsa |
| Abbvie INC. | $82.01 | 2024 | |
| Taiho Oncology, INC. | $79.86 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.51 | 2023-2025 | |
| Stemline Therapeutics INC. | $67.56 | 2023 | Orserdu |
| Sobi, INC | $66.99 | 2022-2024 | |
| Lilly USA, LLC | $63.43 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Genmab U.S., INC. | $61.88 | 2023-2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.89 | 2025 | |
| Blueprint Medicines Corporation | $52.45 | 2023-2024 | Ayvakit |
| Adc Therapeutics America, INC. | $51.14 | 2022-2025 | |
| Puma Biotechnology, INC. | $44.90 | 2023-2024 | |
| Novo Nordisk INC | $37.48 | 2025 | Alhemo |
| Myovant Sciences INC. | $37.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $37.11 | 2023-2024 | Ultomiris |
| Immunogen, INC. | $32.49 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $30.90 | 2024 | Qinlock |
| Servier Pharmaceuticals LLC | $30.32 | 2024-2025 | |
| Morphosys, US INC. | $30.10 | 2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $28.84 | 2023 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $28.55 | 2024-2025 | Sancuso |
| Emd Serono, INC. | $28.36 | 2022-2025 | |
| Array Biopharma INC | $20.05 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $18.63 | 2024 | Krazati |
| Gilead Sciences, INC. | $18.17 | 2023 | |
| Immunocore Limited | $17.69 | 2024 | Kimmtrak |
| Corcept Therapeutics | $16.70 | 2025 | Korlym |
| Caris Mpi, INC. | $16.54 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $15.82 | 2023 | Fotivda |
| Beone Medicines USA, INC. | $15.43 | 2025 | Tevimbra |
| Myriad Genetic Laboratories, INC. | $14.42 | 2025 | Myrisk |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $13.20 | 2024 | Rolvedon |
| Coherus Oncology, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mattei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.